ClinicalTrials.gg
CompletedNCT05373953Updated Apr 15, 2024

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

A Phase 1 interventional study of CHF6001 in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Bulgaria. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
7th of 12
44 · median 46
Started
2022
the only one that year
Phase 1
7 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
12 of 12
Chiesi Farmaceutici S.p.A.

Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 1, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tanimilast

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects:

    1. Subject's written obtained prior to any study-related procedure;
    2. Ability to understand the study procedures and the risks involved, and ability to be rained to use the inhalers correctly and to generate sufficient peak inspiratory flow (PIF; at least 40 L/min) using the In- Check DIAL set as per NEXThaler® inhaler resistance;
    3. 12-Lead digitised (ECG) in triplicate considered as normal (40 beats per minute [bpm] ≤ heart rate [HR] ≤ 110 bpm, 120 ms ≤ PR interval [PR] ≤ 210 ms, QRS interval [QRS] ≤ 120 ms, corrected using Fridericia's formula [QTcF] ≤ 450 ms for males and QTcF ≤ 470 ms for females) at screening visit. The mean value must be within the defined range;
    4. Male and female subjects aged 40 to 80 years inclusive;
    5. Subjects must weigh at least 45 kg for females and 50 kg for males to participate in the study, and must have a within the range of 18 to 35 kg/m2 inclusive;
    6. Non- or ex-smokers who smoked \< 5 pack-years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year prior to screening;
    7. Female subjects: a. Women of (WOCBP) fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use at least an acceptable effective method from the signature of the informed consent and until study discontinuation; or ii. WOCBP with non-fertile male partners (contraception is not required in this case); b. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile. Tubal ligation or partial surgical interventions are not acceptable.
    8. Vital signs within normal limits at screening: diastolic blood pressure (DBP) 40-89 mmHg and systolic blood pressure (SBP) 90-139 mmHg, extremes included (two measures performed after at least 5 minutes of resting).
    9. Body temperature \< 37.5°C at screening and prior to study treatment administration;
    10. Lung function measurements within normal limits at screening: forced expiratory volume within the first second () > 80% predicted and FEV1/forced vital capacity (FVC) ratio > 0.70;

      Healthy subjects only:

    11. Good mental and physical status, determined on the basis of the medical history and a general clinical examination, at screening and prior to study treatment administration;
    12. Matched to at least one liver impaired subject enrolled in the study with respect to race, gender, age (±10 years) and body weight (±15%)

      Liver impaired subjects only:

    13. Documented chronic stable liver disease based on the score and classification (Child-Pugh Class A [mild], B [moderate] or C [severe]) at screening and on Day -1:
    14. Liver impairment must be caused by hepatic primary disease, not a complication of other underlying diseases.

Exclusion criteria

Exclusion Criteria:

  • All subjects:

    1. For females only: pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed prior to study treatment administration;
    2. Subjects with history of breathing problems (i.e. history of asthma including childhood asthma);
    3. Positive (HIV) 1 or HIV2 serology at screening;
    4. Subject has pre-planned surgery or procedures that would interfere with the conduct of the study;
    5. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks, or complications from this disease, which has not resolved within 14 days prior to screening or prior to study treatment administration;
    6. Blood donation or blood loss (≥ 450 mL) less than 2 months prior to screening or prior to study treatment administration;
    7. Abnormal level defined as \< 13 g/dL for males and \< 11 g/dL for females at screening;
    8. Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen evaluated at screening or prior to study treatment administration;
    9. Intake of non-permitted concomitant medications in the predefined period prior to screening or prior to study treatment administration, or the subject is expected to take non-permitted concomitant medications during the study
    10. Unsuitable veins for repeated venepuncture;
    11. Participation in another clinical study where an treatment was received, and last investigations were performed less than 8 weeks prior to screening;
    12. Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or to study treatment administration;
    13. Known intolerance and/or to any of the contained in the formulation used in the study;
    14. Heavy caffeine drinker (average of > 5 cups or glasses per day of caffeinated beverages e.g. coffee, tea, cola, calculated by number of standard espresso portions);
    15. Positive urine test for cotinine at screening or prior to study treatment administration;
    16. /warnings/precaution for use: contra-indications to the investigational medicinal product constitute an exclusion criterion. For warnings/precaution for use, eligibility will be judged by the Investigator;
    17. The use of any kind of smoking electronic devices within 6 months before screening and before study treatment administration;
    18. and/or uncontrolled cardiovascular, renal, gastrointestinal, haematological, endocrine, metabolic, respiratory, neurologic, neoplastic or psychiatric disorder that, based on the Investigator's judgment, may interfere with successful completion of this study.

      Healthy subjects only:

    19. Any hepatic disorder that, based on the Investigator's medical judgment, may interfere with successful completion of this study;
    20. Positive results from the hepatitis serology which indicate acute or chronic or (e.g. positive hepatitis B surface antigen [HBsAg], hepatitis B core antibody [immunoglobulin M antibody to hepatitis B core antigen; IgM anti-HBc], hepatitis C virus [HCV] antibody); Note: Subjects with an isolated antibody to HBsAg (anti-HBs) positive result, immune due to a medical history of vaccination, are permitted;
    21. Abnormal liver enzymes at screening or prior to study treatment administration ( [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpeptidase, alkaline phosphatase or total ; ALT or AST > 1.5 times the [ULN], bilirubin > 1.5 times the ULN);
    22. Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test at screening or prior to study treatment administration;
    23. Clinically relevant abnormal laboratory values at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment;

      Liver impaired subjects only:

    24. Impaired renal function (estimated [eGFR] \< 60 mL/min/1.73 m2) due to primary or secondary renal disease (e.g. hepatorenal syndrome);
    25. Documented history of alcohol abuse within at least 3 months prior to screening or a positive alcohol breath test at screening or prior to study treatment administration;
    26. Severe complications of liver disease within the preceding 3 months prior to enrolment (e.g. Grade 3-4 encephalopathy, severe ascites, severe haemostatic impairment, gastrointestinal haemorrhage, spontaneous bacterial peritonitis or emergency room visit/hospitalisation due to liver disease);
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    mild impairment subjects

    Administration of a single dose of CHF6001 800 µg in mild impairment subjects

    Drug: CHF6001

  • Experimental
    moderate impairment subjects

    Administration of a single dose of CHF6001 800 µg in moderate impairment subjects

    Drug: CHF6001

  • Experimental
    severe impairment subjects

    Administration of a single dose of CHF6001 800 µg in severe impairment subjects

    Drug: CHF6001

  • Active comparator
    healthy volunteers

    Administration of a single dose of CHF6001 800 µg in healthy volunteers

    Drug: CHF6001

Interventions

  • CHF6001 will be administered using the NEXThaler® DPI device

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter (Cmax)

    Peak Plasma Concentration (Cmax) for CHF6001 for total plasma

    Time frame: Over 240 hours after administration in blood

  2. Pharmacokinetic parameter (AUCt)

    Area under the plasma concentration versus time curve (AUCt) for CHF6001 for total plasma

    Time frame: Over 240 hours after administration in blood

Secondary outcomes

  1. Pharmacokinetic parameter ( Cmax)

    Peak Plasma Concentration (Cmax) for CHF6001 unbound plasma

    Time frame: Over 240 hours after administration in blood

  2. Pharmacokinetic parameter (AUCt)

    Area under the plasma concentration versus time curve (AUCt) for CHF6001 unbound plasma

    Time frame: Over 240 hours after administration in blood

  3. Pharmacokinetic parameter (AUC0-72)

    Area under plasma concentration from 0 to 72hours (AUC0-72) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 72 hours after administration in blood

  4. Pharmacokinetic parameter (AUC0-240)

    Area under plasma concentration from 0 to 240hours (AUC0-240) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

  5. Pharmacokinetic parameter (AUC0-∞)

    Area under plasma concentration from 0 to infinity(AUC0-∞) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

  6. Pharmacokinetic parameter (tmax)

    Time of the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

  7. Pharmacokinetic parameter (t1/2)

    Terminal half-life (t1/2) for CHF6001, CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

  8. Pharmacokinetic parameter (CL/F)

    Apparent systemic clearance (CL/F) for CHF6001

    Time frame: Over 240 hours after administration in blood

  9. Pharmacokinetic parameter (AUCt)

    Area under the plasma concentration versus time curve (AUCt) for CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

  10. Pharmacokinetic parameter (Cmax)

    Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095

    Time frame: Over 240 hours after administration in blood

07

Study locations

1 site
  • MC Comac Medical Ltd.
    Sofia, 1618, Bulgaria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Nov 2022, 6 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 6 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 13, 2022
StartActual
May 5, 2022
Primary completionActual
Nov 25, 2022
CompletionActual
Nov 25, 2022
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373953
Responsible party
Sponsor
First posted
May 13, 2022
Start date
May 5, 2022
Primary completion
Nov 25, 2022
Completion
Nov 25, 2022
Last update
Apr 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion